Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma (COACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01487915

Recruitment Status : Unknown

Verified September 2014 by JLee, Asan Medical Center.
Recruitment status was: Recruiting

First Posted : December 8, 2011

Last Update Posted : September 25, 2014

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

JLee, Asan Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 2015
Study Completion Date :	No date given

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). Eur J Cancer. 2020 Mar;127:183-190. doi: 10.1016/j.ejca.2019.08.034. Epub 2019 Oct 24.

To Top